These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862 [TBL] [Abstract][Full Text] [Related]
11. Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxis. Degen O; ven Lunzen J; Horstkotte MA; Sobottka I; Stellbrink HJ AIDS; 2002 Jul; 16(10):1433-4. PubMed ID: 12131226 [No Abstract] [Full Text] [Related]
12. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. Jacobson MA; French M AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998 [TBL] [Abstract][Full Text] [Related]
13. P. carinii prophylaxis in patients with HIV. Kirchner JT Am Fam Physician; 1999 Nov; 60(7):2094-5. PubMed ID: 10569511 [No Abstract] [Full Text] [Related]
14. Relapse of CMV retinitis in an AIDS patient with high CD4 counts. Petit N; Zandotti C; Riss JM; Frippiat F; Moulin JF; Gastaut JA J Antimicrob Chemother; 1998 Jun; 41(6):666-7. PubMed ID: 9687110 [No Abstract] [Full Text] [Related]
15. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Vibhagool A; Sungkanuparph S; Mootsikapun P; Chetchotisakd P; Tansuphaswaswadikul S; Bowonwatanuwong C; Ingsathit A Clin Infect Dis; 2003 May; 36(10):1329-31. PubMed ID: 12746781 [TBL] [Abstract][Full Text] [Related]
16. Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy. Powderly WG Clin Infect Dis; 2000 Aug; 31(2):597-601. PubMed ID: 10987727 [TBL] [Abstract][Full Text] [Related]
17. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172 [TBL] [Abstract][Full Text] [Related]
18. Discontinuation of prophylaxis in HAART-responders. Maenza J Hopkins HIV Rep; 1999 Jul; 11(4):2-3. PubMed ID: 11366923 [TBL] [Abstract][Full Text] [Related]
19. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections. Fichtenbaum CJ Res Initiat Treat Action; 1998 Jul; 4(4):3-7. PubMed ID: 11365645 [TBL] [Abstract][Full Text] [Related]
20. [A changed pattern of opportunistic infections and malignancies in HIV-seropositive patients after the introduction of intensive anti-HIV-combination therapy]. Borleffs JC; Schneider MM; Hoepelman IM Ned Tijdschr Geneeskd; 1998 Oct; 142(44):2395-9. PubMed ID: 9864534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]